Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

learn more about the effects of smell retraining therapy on smell loss following COVID-19 and to determine if budesonide-saline irrigations make smell retraining therapy more effective.

  • 0 views
  • 10 Oct, 2021
  • 1 location
  • 0 views
  • 25 Jan, 2022
  • 1 location
Diesel Exhaust Induces Glucocorticoid Resistance (DIGR)

for 2 hours breathing either filtered air or diluted diesel exhaust. Samples will be collected before and after exposure to analyze the effects of budesonide and diesel exhaust exposure.

  • 0 views
  • 01 Feb, 2022
  • 1 location
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 10% From Pre Transplantation

are used: Bergeron et al. reported improvements in symptoms as well in FEV1 one month followed treatment including formoterol and budesonide in a prospective trial including adults (12% increase of

  • 0 views
  • 13 Jun, 2021
  • 1 location
Control Crohn Safe Trial

efficacy and safety of periodic adalimumab as initial treatment in newly diagnosed CD patients compared to standard step-care with corticosteroid/budesonide as the initial treatment

corticosteroids
combination therapy
tumor necrosis factor
MRI
monoclonal antibodies
  • 0 views
  • 30 May, 2021
  • 5 locations
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients

Thoracic lung cancer treatment often induces lung toxicity as an adverse effect of concomitant therapy (CCRT) using chemo or target therapy drugs in addition to radiation therapy, in non-small cell lung cancer (NSCLC) patients with advanced disease. The presence of Pneumonitis is the most severe acute lung injury derived from …

  • 1 views
  • 17 Feb, 2021
  • 2 locations
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis (SARCORT)

For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is 20-40 mg per day.5 The exact dose and duration of treatment for sarcoidosis are unknown.4 We hypothesize …

pulmonary sarcoidosis
granulomatous disease
glucocorticoids
immunosuppressants
immunosuppressive agents
  • 68 views
  • 13 May, 2022
  • 1 location
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study (REScUE-OLE)

The aim of the study is to assess the long-term efficacy and safety of a ustekinumab 90mg subcutaneous (SC) every 4 weeks (Q4w) regimen in patients with Crohn's disease previously enrolled in the REScUE study (NCT04245215) because of secondary loss of response to a ustekinumab 90mg SC every 8 weeks …

crohn's disease
ustekinumab
  • 0 views
  • 23 Apr, 2022
  • 1 location
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)

Using various types of inhalers is the treatment cornerstone for COPD patients to control their symptoms. Many inhaler devices require minimum inspiratory effort to activate the device, COPD patients commonly use such devices. Those devices deliver the medications only when the patient forcefully inhales so the drug can reach the …

Accepts healthy volunteers
dyspnea
  • 214 views
  • 08 Apr, 2022
  • 1 location
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI) (EBISU)

This study is primarily aimed to investigate whether PROs can be improved after the initiation of BGF pMDI in real world clinical settings. While the study is 12-weeks in duration, the initial 4-week period will be used to assess immediate onset of benefits while the full study length will serve …

  • 0 views
  • 15 Jun, 2022
  • 4 locations